MetaCap

Voyager Therapeutics (VYGR) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Voyager Therapeutics (VYGR) has outperformed Zura Bio (ZURA) over the past year, losing 63.4% versus a loss of 74.4%. Voyager Therapeutics is the larger company by market cap ($95.2 million vs $89.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VYGR-63.40%ZURA-74.37%
+102%+10%-83%
Nov 21, 20251 yearNov 20, 2026
VYGR-79.24%ZURA-96.84%
+87%-9%-106%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VYGR versus ZURA key metrics
MetricVYGRZURA
Share price$1.53$0.9305
Market cap$95.21M$89.63M
1-day change-4.97%-2.30%
YTD return-61.07%-82.24%
1-year return-63.40%-74.37%
5-year return-50.00%—
EPS (TTM)$-1.74$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$40.37M—
Revenue growth (YoY)-49.53%—
Net income (latest FY)$-119.72M$-68.65M
Operating margin-326.56%—
Net margin-296.53%—
52-week high$5.48$7.44
52-week low$1.48$0.919
Distance from 52-week high-72.08%-87.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+829.41%+759.75%
Average volume770.24K4.47M
Shares outstanding62.23M96.33M
Employees14140
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VYGR has outperformed ZURA by 11.0 percentage points over the past year.

About Voyager Therapeutics

VYGR stock →

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

VYGR vs ZURA FAQ

Which is bigger, Voyager Therapeutics or Zura Bio?

Voyager Therapeutics (VYGR) is larger, with a market capitalization of $95.21M compared with $89.63M for Zura Bio (ZURA).

Which stock has performed better over the past year, VYGR or ZURA?

VYGR returned -63.40% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.

Are Voyager Therapeutics and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons